e-learning
resources
Amsterdam 2011
Wednesday, 28.09.2011
Role of the biomarkers in airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes?
G. E. Carpagnano, A. Koutelou, A. Depalo, L. Bergantino, C. Ruggeri, D. Lacedonia, M. P. Foschino Barbaro (Foggia, Italy)
Source:
Annual Congress 2011 - Role of the biomarkers in airway diseases
Session:
Role of the biomarkers in airway diseases
Session type:
Poster Discussion
Number:
4787
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. E. Carpagnano, A. Koutelou, A. Depalo, L. Bergantino, C. Ruggeri, D. Lacedonia, M. P. Foschino Barbaro (Foggia, Italy). Could exhaled ferritin and SOD be used as markers for lung cancer and prognosis prediction purposes?. Eur Respir J 2011; 38: Suppl. 55, 4787
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Early detection of lung cancer through analysis of VOC biomarkers in exhaled breath: The LuCID study.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Dermcidin identification from exhaled air for lung cancer diagnosis
Source: Eur Respir J 2010; 35: 1182-1185
Year: 2010
Can exhaled nitric oxide (FeNO) predict radiotherapy-induced lung toxicity in lung cancer patients?
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011
Free plasmatic circulating DNA as prognostic and diagnostic lung cancer biomarker
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Exhaled aldehydes as markers of disease in lung cancer patients
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
Source: Eur Respir J 2004; 24: Suppl. 48, 77s
Year: 2004
Protein markers in the exhaled breath condensate of lung carcinoma patients
Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Year: 2012
Pretreatment levels of TNF-α in serum and exhaled breath condensate in patients with lung cancer
Source: Annual Congress 2007 - Biology of thoracic malignancies
Year: 2007
The value of adiponectin as an inflammatory marker in lung cancer?
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
Source: Eur Respir J 2015; 46: 1773-1780
Year: 2015
Evaluation of serum tumour markers in the lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Vascular endothelial growth factor (VEGF) in serum and exhaled breath condensate (EBC) as a potential biomarker for early detection of non-small cell lung cancer (NSCLC)
Source: Annual Congress 2008 - Biology in thoracic tumours
Year: 2008
Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate
Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors
Year: 2017
Pretreatment levels of VEGF and 8-isoprostane in exhaled breath condensate (EBC) and serum of lung cancer patients
Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology
Year: 2008
The clinical significance of growth factors measurement in exhaled breath condensates (EBC) among patients with interstitial lung diseases
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Comparison of exhaled biomarkers to other markers of airway diseases
Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept